ClinicalTrials.gg
RecruitingNCT07365319TeLuRide-008Updated Nov 16, 2026

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

A Phase 2/3 interventional study of EIK1001 and Pembrolizumab (KEYTRUDA®) in Non Small Cell Lung Cancer (Squamous or Non Squamous) and Stage 4 NSCLC, sponsored by Eikon Therapeutics. Recruiting at 52 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Eikon Therapeutics · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 16, 2026First sites in 11 new countries28 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
125th of 2,995
750 · median 56
Started
2026
with 128 others
Phase 2/3
29 of 3,368
8 open now
Primary completion
2035-12
later than 882 of 892 live
Registered
3,269th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 125th largest by planned enrollment of the 2,995 interventional ones that give a count, is one of 129 that started in 2026, is one of 29 in phase 2/3, reaches primary completion later than 882 of the 892 other live ones, and was the 3,269th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Read the detailed description

This is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered IV in combination with pembrolizumab and histologically appropriate chemotherapy (pemetrexed plus either carboplatin or cisplatin) to participants with Stage 4 non-squamous or (carboplatin plus either paclitaxel or nab-paclitaxel) for participants with squamous NSCLC who have not received prior systemic therapy. The study is conducted in 2 phases (Phase 2 and Phase 3) and analyzed in 3 parts (dose optimization, dose expansion and confirmatory hypothesis testing).

03

Conditions studied

  • Non Small Cell Lung Cancer (Squamous or Non Squamous)
  • Stage 4 NSCLC

Keywords

  • Non Small Cell Lung Cancer
  • EIK1001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant must be ≥ 18 years old at the time of signing the .
  2. Participant has a of at least 3 months.
  3. Participant has or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC.
  4. Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved targeted therapies are available to the participant in their respective country.
  5. Participant has at least 1 lesion with at Baseline according to 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
  6. Participant has not received prior systemic therapy for advanced/ NSCLC.

    Note: Participants who received or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible.

  7. Participant has an Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment.
  8. Participant has tumor tissue available for testing from a site that was not radiated prior to , and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is \< 3yrs old).

Key Exclusion Criteria:

  1. has small cell elements present histologically and/or the tumors are not predominantly non-squamous or squamous NSCLC.
  2. is currently actively enrolled in or has recently participated in a study of an agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo.
  3. has had major surgery (\< 3 weeks prior to the first dose of study intervention administration).
  4. has received a live-virus vaccination within 30 days of the start of study intervention initiation.
  5. has received radiation therapy within 7 days of the first dose of study intervention administration.
  6. has completed palliative radiotherapy within 7 days of the first dose of study intervention administration.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
750 participants (estimated)

Study arms

  • Placebo comparator
    Arm 1 (Placebo in Combination with SOC)

    Participants in this arm will receive EIK1001 Placebo + Standard of Care (SOC).

    Drug: Pembrolizumab (KEYTRUDA®) · Drug: Placebo · Drug: Paclitaxel + Carboplatin · Drug: Nab-paclitaxel + Carboplatin · Drug: Pemetrexed + Cisplatin /Carboplatin

  • Experimental
    Arm 2 (EIK1001 in Combination with SOC)

    Participants in this arm will receive EIK1001 (Selected Dose 1) + Standard of Care (SOC).

    Drug: EIK1001 · Drug: Pembrolizumab (KEYTRUDA®) · Drug: Paclitaxel + Carboplatin · Drug: Nab-paclitaxel + Carboplatin · Drug: Pemetrexed + Cisplatin /Carboplatin

  • Experimental
    Arm 3 (EIK1001 in Combination with SOC)

    Participants in this arm will receive EIK1001 (Selected Dose 2) + Standard of Care (SOC).

    Drug: EIK1001 · Drug: Pembrolizumab (KEYTRUDA®) · Drug: Paclitaxel + Carboplatin · Drug: Nab-paclitaxel + Carboplatin · Drug: Pemetrexed + Cisplatin /Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by BICR, or death due to any cause, whichever occurs first

    Time frame: Through study completion, up to 6 years

  2. Overall survival (OS)

    OS defined as the time from the first dose of study medication to death due to any cause

    Time frame: Through study completion, up to 10 years

  3. Objective Response (OR)

    Objective response (OR) is defined as participants who demonstrate complete response (CR) or partial response (PR) by RECIST 1.1 as assessed by the Investigator, adverse events (AEs), and discontinuation of study intervention due to an AE (Dose Optimization Only).

    Time frame: Through study completion, up to 6 years

Secondary outcomes

  1. Objective response (OR)

    Objective response (OR) is defined as participants who have a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 by BICR

    Time frame: Up to 6 years

  2. Duration of response (DOR)

    DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by BICR.

    Time frame: Up to 6 years

  3. Progression-free survival (PFS) by Investigator

    Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by Investigator, or death due to any cause, whichever occurs first.

    Time frame: Up to 6 years

  4. Overall Response Rate (ORR) by Investigator

    Objective Response as defined by participants who demonstrate confirmed CR or PR according to RECIST 1.1 by Investigator.

    Time frame: Up to 6 years

  5. Duration of Response (DOR) by Investigator

    DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by Investigator.

    Time frame: Up to 6 years

  6. Incidence of Adverse Events (AEs)

    Adverse Events (AEs) and discontinuation of study treatment due to any AE.

    Time frame: Up to 2.5 years

07

Study locations

52 of 52 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2035, 114 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 114 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 26, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2040
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
28 sites added — first sites in South Africa, South Korea, Belgium, Germany, Greece and 6 more
All 11 countries

South Africa, South Korea, Belgium, Germany, Greece, Poland, Austria, Brazil, Argentina, Italy, Romania

Show 28 added (6 Brazil, 5 South Korea, 3 Greece, 2 South Africa, 2 Germany, 2 United States, 1 Australia, 1 Belgium, 1 Poland, 1 Austria, 1 Spain, 1 Argentina, 1 Italy, 1 Romania)
  • Sunshine Hospital - Western Health · Saint Albans, Australia
  • Task Eden · George, South Africa
  • Yeungnam University College of Medicine · Daegu, South Korea
  • Gachon University - Gil Medical Center · Incheon, South Korea
  • Centre Hospitalier Universitaire Brugmann · Brussels, Belgium
  • University Hospital Carl Gustav Carus Dresden · Dresden, Germany
  • Henry Dunant Hospital Center · Athens, Greece
  • GCPMED Sp. z o.o., Centrum Medyczne iMed24 · Krakow, Poland
  • Omnicure Clinical Research · Doral, United States
  • The Center for Cancer and Blood Disorders · Fort Worth, United States
  • Kepler Universitaetsklinikum · Linz, Austria
  • Hospital Evangélico de Cachoeiro de Itapemirim · Cachoeiro de Itapemirim, Brazil
  • Nucleo de Oncologia da Bahia · Salvador, Brazil
  • Oncoclinicas Rio de Janeiro · Rio de Janeiro, Brazil
  • Katholische Marienkrankenhaus gGmbH · Hamburg, Germany
  • The Medical Oncology Centre of Rosebank · Saxonwold, South Africa
  • Chonnam National University Hwasun Hospital (CNUHH) · Hwasun, South Korea
  • Hospital Regional Universitario de Malaga · Málaga, Spain
  • Fundación de Estudios Clínicos · Rosario, Argentina
  • CRIO - Centro Regional Integrado de Oncologia · Fortaleza, Brazil
  • Clinica de Hematologia e Oncologia Viver Ltda · Santa Maria, Brazil
  • Hospital Brasília Unidade Lago Sul · Brasília, Brazil
  • Hospital Genesis · Thessaloniki, Greece
  • 4th Department of Medical Oncology, European Interbalkan Medical Center · Thessaloniki, Greece
  • Policlinico Campus Bio-Medico · Roma, Italy
  • Medisprof Cancer Center · Cluj-Napoca, Romania
  • Korea University Medical Center-Korea University Guro Hospital - Women's Cancer Center · Seoul, South Korea
  • Kangbuk Samsung Medical Center (KBSMC) · Seoul, South Korea
across 4 updates, Oct 2, 2026 – Nov 16, 2026
Show all 4 updates
  1. Nov 16, 2026
    10 sites added — first sites in Argentina, Italy and Romania
    Show 10 added (3 Brazil, 2 Greece, 2 South Korea, 1 Argentina, 1 Italy, 1 Romania)
    • Fundación de Estudios Clínicos · Rosario, Argentina
    • CRIO - Centro Regional Integrado de Oncologia · Fortaleza, Brazil
    • Clinica de Hematologia e Oncologia Viver Ltda · Santa Maria, Brazil
    • Hospital Brasília Unidade Lago Sul · Brasília, Brazil
    • Hospital Genesis · Thessaloniki, Greece
    • 4th Department of Medical Oncology, European Interbalkan Medical Center · Thessaloniki, Greece
    • Policlinico Campus Bio-Medico · Roma, Italy
    • Medisprof Cancer Center · Cluj-Napoca, Romania
    • Korea University Medical Center-Korea University Guro Hospital - Women's Cancer Center · Seoul, South Korea
    • Kangbuk Samsung Medical Center (KBSMC) · Seoul, South Korea
  2. Nov 3, 2026
    10 sites added — first sites in Austria and Brazil
    Show 10 added (3 Brazil, 2 United States, 1 Austria, 1 Germany, 1 South Africa, 1 South Korea, 1 Spain)
    • Omnicure Clinical Research · Doral, United States
    • The Center for Cancer and Blood Disorders · Fort Worth, United States
    • Kepler Universitaetsklinikum · Linz, Austria
    • Hospital Evangélico de Cachoeiro de Itapemirim · Cachoeiro de Itapemirim, Brazil
    • Nucleo de Oncologia da Bahia · Salvador, Brazil
    • Oncoclinicas Rio de Janeiro · Rio de Janeiro, Brazil
    • Katholische Marienkrankenhaus gGmbH · Hamburg, Germany
    • The Medical Oncology Centre of Rosebank · Saxonwold, South Africa
    • Chonnam National University Hwasun Hospital (CNUHH) · Hwasun, South Korea
    • Hospital Regional Universitario de Malaga · Málaga, Spain
    + 1 other change: verification date
  3. Oct 20, 2026
    4 sites added — first sites in Belgium, Germany, Greece and Poland
    Show 4 added (1 Belgium, 1 Germany, 1 Greece, 1 Poland)
    • Centre Hospitalier Universitaire Brugmann · Brussels, Belgium
    • University Hospital Carl Gustav Carus Dresden · Dresden, Germany
    • Henry Dunant Hospital Center · Athens, Greece
    • GCPMED Sp. z o.o., Centrum Medyczne iMed24 · Krakow, Poland
    + 1 other change: verification date
  4. Oct 2, 2026
    4 sites added — first sites in South Africa and South Korea
    Show 4 added (2 South Korea, 1 Australia, 1 South Africa)
    • Sunshine Hospital - Western Health · Saint Albans, Australia
    • Task Eden · George, South Africa
    • Yeungnam University College of Medicine · Daegu, South Korea
    • Gachon University - Gil Medical Center · Incheon, South Korea

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07365319
Lead sponsor
Eikon Therapeutics
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Jun 15, 2026
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2040 (estimated)
Last update
Nov 16, 2026

Study contacts

Elelta Shiferraw
Contact
shiferrawe@eikontx.com
314-209-3659
Nishitha Reddy
study director · Eikon Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion